Sunpharma finally gets USFDA nod for its Halol plant after 2 years

Sun pharma which had earlier received Voluntary Action Indicated (VAI) for its Halol facility finally received much awaited Establishment inspection report for the same.

bloombergquint2018-06432dc9d1-5f97-4a25-930c-86e036bd3632sun_pharma

 

Why is this important

The Halol facility currently accounts for 11 percent of U.S. sales and about 4 percent of total sales—down from 22 percent and 12 percent, respectively, before it ran into regulatory trouble with USFDA. Further the research arm of Sun pharma had two important drugs- Xelpros (for eye disease called Glaucoma) and Elepsia XR (for seizures) that were to be manufactured at Halol.  With receipt of EIR for Halol, it will be important for Sun pharma to ramp up its operations.

Impact on stock

The news is positive for stock of Sun pharma (CMP: Rs 545, M.cap: Rs 130915 cr, 21x FY20E P/E).

Want to know more? Click here

 

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.